1. Home
  2. BIO vs JHG Comparison

BIO vs JHG Comparison

Compare BIO & JHG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BIO
  • JHG
  • Stock Information
  • Founded
  • BIO 1952
  • JHG 1934
  • Country
  • BIO United States
  • JHG United Kingdom
  • Employees
  • BIO N/A
  • JHG N/A
  • Industry
  • BIO Biotechnology: Laboratory Analytical Instruments
  • JHG Investment Managers
  • Sector
  • BIO Industrials
  • JHG Finance
  • Exchange
  • BIO Nasdaq
  • JHG Nasdaq
  • Market Cap
  • BIO 6.9B
  • JHG 5.8B
  • IPO Year
  • BIO N/A
  • JHG N/A
  • Fundamental
  • Price
  • BIO $249.64
  • JHG $32.82
  • Analyst Decision
  • BIO Strong Buy
  • JHG Buy
  • Analyst Count
  • BIO 4
  • JHG 12
  • Target Price
  • BIO $396.50
  • JHG $41.83
  • AVG Volume (30 Days)
  • BIO 385.0K
  • JHG 1.8M
  • Earning Date
  • BIO 05-01-2025
  • JHG 05-01-2025
  • Dividend Yield
  • BIO N/A
  • JHG 5.31%
  • EPS Growth
  • BIO N/A
  • JHG 8.02
  • EPS
  • BIO N/A
  • JHG 2.56
  • Revenue
  • BIO $2,566,500,000.00
  • JHG $2,473,200,000.00
  • Revenue This Year
  • BIO $0.88
  • JHG $2.62
  • Revenue Next Year
  • BIO $4.44
  • JHG $6.26
  • P/E Ratio
  • BIO N/A
  • JHG $11.48
  • Revenue Growth
  • BIO N/A
  • JHG 17.67
  • 52 Week Low
  • BIO $215.38
  • JHG $28.26
  • 52 Week High
  • BIO $387.99
  • JHG $46.68
  • Technical
  • Relative Strength Index (RSI)
  • BIO 49.87
  • JHG 44.82
  • Support Level
  • BIO $232.53
  • JHG $29.29
  • Resistance Level
  • BIO $260.00
  • JHG $33.06
  • Average True Range (ATR)
  • BIO 12.19
  • JHG 1.73
  • MACD
  • BIO 2.60
  • JHG 0.31
  • Stochastic Oscillator
  • BIO 71.26
  • JHG 73.36

About BIO Bio-Rad Laboratories Inc.

Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (56% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (44% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (42% of 2023 sales), Europe (31%), Asia (31%), and other (6%). Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.

About JHG Janus Henderson Group plc

Janus Henderson Group provides investment management services to retail intermediary (56% of managed assets), self-directed (23%) and institutional (21%) clients. At the end of September 2024, active equities (63%), fixed-income (21%), multi-asset (14%) and alternative (2%) investment platforms constituted the company's $382.3 billion in assets under management. Janus Henderson sources most of its managed assets from clients in North America (61%), with customers from Europe, the Middle East, Africa, and Latin America (29%) and the Asia-Pacific region (10%) accounting for the remainder.

Share on Social Networks: